Non-selective NMDA receptor antagonism produces rapid symptom improvement in treatment-resistant depression; however, associated side effects necessitate medical oversight during administration. We hypothesised that selective GluN2A antagonism could provide similar efficacy with an improved side effect profile. Here, we report the pharmacology of JNJ-78911118, a brain-penetrant, GluN2A...
Salvia species native to the Americas are rich in valuable bioactive furanoclerodanes like the psychoactive salvinorin A found in Salvia divinorum, which is used in the treatment of opioid addiction. However, relatively little is known about their biosynthesis. To address this, we investigated the biosynthesis of salviarin, the most abundant furanoclerodane structure in the ornamental sage...
This paper explores the potential for reconceptualizing cognition beyond brain-centered and anthropocentric readings, highlighting the entanglement between the body, the environment, and emerging technologies. Critiquing the limitations of computationalist and reductionist perspectives as well as rejecting any possible unifying definition of the phenomenon of cognition, I advocate for a...
Although secular mindfulness interventions draw from contemplative traditions emphasizing relationality, evidence for impacts of such interventions on relational outcomes remains inconsistent. This study was designed to clarify conditions under which mindfulness training can improve relational functioning in a perinatal context where quality of relationship-building carries particularly...
Microdosing, the repeated use of psychedelic substances at low doses, is growing in popularity among recreational consumers. While this practice is associated with many benefits to mood, well-being and health, research in this area is in its early stages and predominantly centered on human applications. In this narrative review, we synthesize the findings from studies investigating the effects...
Repeated ketamine treatment to maintain a rapid antidepressant effect can lead to side effects over time, highlighting an unmet clinical need for sustaining this drug's antidepressant action from a single administration. Ketamine-induced synaptic potentiation at CA3-CA1 synapses has been proposed to be a key synaptic substrate for antidepressant action. Here, we found that ketamine-induced...
(S)-Ketamine, which is used to treat depression, has significant undesirable effects and has potential for abuse. A safe alternative to (S)-ketamine is (R)-ketamine. The relationship between (R)-ketamine and the mGlu5 receptor is unknown, although screening tests indicate the possibility of potentiation of the antidepressant effect of (R)-ketamine by the mGlu5 receptor negative allosteric...
Medical research in psychedelics in the West has re-emerged in the 21st century after the research in the 1950s and early 1960s had collapsed by 1966 (Pollan 2018, 220). The results of recent research have been promising in the treatment of anxiety in terminal cancer patients and in the treatment of addiction and depression. Even at this early stage, the beneficial effects of psychedelics in...
Australia has become the first country to approve the use of psychedelics, namely MDMA and psilocybin, for clinical treatment of post-traumatic stress disorder and treatment-resistant depression. Here, we briefly explore the history of its use, how it works, and the hope it may provide people receiving end-of-life care.
Background: Opioid use disorder (OUD) is a debilitating health condition that is associated with significant morbidity and mortality in the U.S. While preliminary studies have demonstrated that psilocybin is associated with lowered odds of OUD, current research in this domain suffers from a lack of investigation into the impact of race/ethnicity on this association. Objective: To assess the...